05:13 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday its drug Tagrisso reduced the risk of disease progression in 84% of patients with inoperable stage 3 epidermal growth factor receptor-mutated lung cancer after chemoradiotherapy vs. a placebo in a phase 3 trial.

The company said the drug, also known as osimertinib, showed a median survival rate of 39.1 months among 143 patients compared with 5.6 months for 73 patients given a placebo.

The company said the testing showed clinically "meaningful" progression-free survival benefits across gender, race, mutation type, age, smoking history, and prior chemoradiotherapy.

Price: 77.84, Change: -0.18, Percent Change: -0.23